{"id":"https://openalex.org/W2949916213","doi":"https://doi.org/10.1002/hon.128_2629","title":"SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B\u2010CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY","display_name":"SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B\u2010CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY","publication_year":2019,"publication_date":"2019-06-01","ids":{"openalex":"https://openalex.org/W2949916213","doi":"https://doi.org/10.1002/hon.128_2629","mag":"2949916213"},"language":"en","primary_location":{"id":"doi:10.1002/hon.128_2629","doi":"https://doi.org/10.1002/hon.128_2629","is_oa":false,"landing_page_url":"https://doi.org/10.1002/hon.128_2629","pdf_url":null,"source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005565037","display_name":"Tanya Siddiqi","orcid":"https://orcid.org/0000-0001-5292-8298","observed_orcids":["https://orcid.org/0000-0001-5292-8298"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Siddiqi","raw_affiliation_strings":["Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, United States","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002103749","display_name":"Jeremy S. Abramson","orcid":"https://orcid.org/0000-0001-8467-9257","observed_orcids":["https://orcid.org/0000-0001-8467-9257"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J.S. Abramson","raw_affiliation_strings":["Center for Lymphoma, Massachusetts General Hospital, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Lymphoma, Massachusetts General Hospital, Boston, United States","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101892220","display_name":"Hannah J. Lee","orcid":"https://orcid.org/0000-0002-1663-9170","observed_orcids":["https://orcid.org/0000-0002-1663-9170"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H.J. Lee","raw_affiliation_strings":["Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052197896","display_name":"S. Schuster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Schuster","raw_affiliation_strings":["Department of Medicine, Abramson Cancer Center, Philadelphia, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Abramson Cancer Center, Philadelphia, United States","institution_ids":["https://openalex.org/I4390039297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112783573","display_name":"Jens Hasskarl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387154805","display_name":"Celgene (Switzerland)","ror":"https://ror.org/055503602","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387154805"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"J. Hasskarl","raw_affiliation_strings":["Global Clinical Research & Development Celgene International Boudry Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Research & Development Celgene International Boudry Switzerland","institution_ids":["https://openalex.org/I4387154805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055579830","display_name":"Sandrine Montheard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387154805","display_name":"Celgene (Switzerland)","ror":"https://ror.org/055503602","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387154805"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"S. Montheard","raw_affiliation_strings":["Global Clinical Research & Development Celgene International Boudry Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Research & Development Celgene International Boudry Switzerland","institution_ids":["https://openalex.org/I4387154805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086159400","display_name":"Justine Dell Aringa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Dell Aringa","raw_affiliation_strings":["Translational Medicine, Immuno Oncology and Cellular Therapy, Juno Therapeutics, a Celgene Company, Seattle, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Medicine, Immuno Oncology and Cellular Therapy, Juno Therapeutics, a Celgene Company, Seattle, United States","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029344208","display_name":"Erik W. Thompson","orcid":"https://orcid.org/0000-0002-9723-4924","observed_orcids":["https://orcid.org/0000-0002-9723-4924"]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Thompson","raw_affiliation_strings":["Informatics and Predictive Sciences, Juno Therapeutics, a Celgene Company, Seattle, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Informatics and Predictive Sciences, Juno Therapeutics, a Celgene Company, Seattle, United States","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056830887","display_name":"Revathi Ananthakrishnan","orcid":"https://orcid.org/0000-0003-1730-3756","observed_orcids":["https://orcid.org/0000-0003-1730-3756"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Ananthakrishnan","raw_affiliation_strings":["Biostatistics, Celgene Corporation, Summit, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Celgene Corporation, Summit, United States","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088179815","display_name":"Matthew Alexander Lunning","orcid":"https://orcid.org/0000-0002-2761-7612","observed_orcids":["https://orcid.org/0000-0002-2761-7612"]},"institutions":[{"id":"https://openalex.org/I59130452","display_name":"University of Nebraska Medical Center","ror":"https://ror.org/00thqtb16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I59130452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Lunning","raw_affiliation_strings":["Hematology/Oncology, University of Nebraska Medical Center, Omaha, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, University of Nebraska Medical Center, Omaha, United States","institution_ids":["https://openalex.org/I59130452"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3500,"currency":"USD","value_usd":3500},"apc_paid":null,"fwci":1.538,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.84233749,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"37","issue":"S2","first_page":"171","last_page":"172"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lisocabtagene-maraleucel","display_name":"lisocabtagene maraleucel","score":0.996999979019165},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8100000023841858},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-non-hodgkin-lymphoma","display_name":"relapsed/refractory B-cell non-Hodgkin lymphoma","score":0.902999997138977},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.953000009059906},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.7200000286102295},{"id":"https://openalex.org/keywords/anti-cd19-antibody","display_name":"anti-CD19","score":0.7799999713897705},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.621999979019165},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6240000128746033},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6600000262260437},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.4970000088214874},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.7929999828338623},{"id":"https://openalex.org/keywords/neurological-events","display_name":"neurological events","score":0.7250000238418579},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.3959999978542328},{"id":"https://openalex.org/keywords/platform-studies","display_name":"platform studies","score":0.3479999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.774054765701294},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.679267406463623},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.6434990763664246},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5647247433662415},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.5610553622245789},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.48708367347717285},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.46254417300224304},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4514351487159729},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.44592583179473877},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41105523705482483},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36495262384414673},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.32146376371383667},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2958621382713318},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2324642837047577},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.17320269346237183},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.16443952918052673},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.16368001699447632},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.08338826894760132},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/hon.128_2629","doi":"https://doi.org/10.1002/hon.128_2629","is_oa":false,"landing_page_url":"https://doi.org/10.1002/hon.128_2629","pdf_url":null,"source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2987075075","https://openalex.org/W3205815135","https://openalex.org/W4281779501","https://openalex.org/W2952171835","https://openalex.org/W3082855561","https://openalex.org/W2954386163","https://openalex.org/W3215188061","https://openalex.org/W2953001506","https://openalex.org/W2954529696","https://openalex.org/W2949261511"],"abstract_inverted_index":{"Introduction:":[0],"In":[1],"the":[2,75,116,126,208,258,267,273,375,423],"ongoing":[3,88],"TRANSCEND":[4],"NHL":[5],"001":[6],"study":[7,95],"(NCT02631044),":[8],"lisocabtagene":[9],"maraleucel":[10],"(liso-cel;":[11],"JCAR017),":[12],"an":[13,185,430],"investigational,":[14],"anti-CD19":[15,82],"chimeric":[16],"antigen":[17],"receptor":[18],"(CAR)":[19],"T":[20,31,84,179,387,403,446],"cell":[21,61,85],"product":[22],"administered":[23],"as":[24,184],"a":[25,39,192,370],"defined":[26],"composition":[27],"of":[28,42,120,140,162,195,244,264,345,366,425,440],"CD4+/CD8+":[29],"CAR":[30,83,386,402,445],"cells,":[32],"has":[33,429],"shown":[34],"high":[35],"response":[36,76,78,360,372],"rates":[37],"and":[38,48,77,142,151,298,304,311,315,331,412],"low":[40],"incidence":[41],"severe":[43],"cytokine":[44],"release":[45],"syndrome":[46],"(CRS)":[47],"neurological":[49],"events":[50,294,328],"(NE)":[51],"in":[52,98,104],"patients":[53],"(pts)":[54],"with":[55,81,100,106,125,149,393,427,451],"relapsed/refractory":[56],"(R/R)":[57],"diffuse":[58,465],"large":[59,466],"B":[60],"lymphoma":[62,109,289,468],"(DLBCL)":[63],"(Abramson":[64],"et":[65],"al,":[66],"ASCO":[67],"2018).":[68],"Immune":[69],"system":[70,102],"modifiers":[71,103],"may":[72],"further":[73,455],"enhance":[74],"durability":[79],"seen":[80],"therapy.":[86],"The":[87,357],"multiarm,":[89],"parallel":[90],"cohort,":[91],"phase":[92],"1/2":[93],"PLATFORM":[94],"evaluates":[96],"liso-cel":[97,124,157,308,426],"combination":[99,424,452],"immune":[101],"pts":[105,132,216,224,232,249,282,323,367,378,383],"R/R":[107,134],"non-Hodgkin":[108],"(NHL).":[110],"We":[111],"report":[112],"preliminary":[113,421],"data":[114,213,443,459],"from":[115,188,276,489,573,649],"dose":[117,164,194,243],"escalation":[118],"part":[119],"Arm":[121],"A,":[122],"combining":[123],"anti-PD-L1":[127],"antibody,":[128],"durvalumab.":[129,441],"Methods:":[130],"Eligible":[131],"had":[133,283,287,324],"B-cell":[135,467],"NHL,":[136],"\u22652":[137],"prior":[138],"lines":[139],"therapy,":[141],"ECOG":[143],"PS":[144],"\u22641.":[145],"Pts":[146],"received":[147,229,380,486,570,646],"lymphodepletion":[148],"fludarabine":[150],"cyclophosphamide":[152],"for":[153,199,504],"3":[154,382],"days":[155],"before":[156],"was":[158,182,205,362,436],"given":[159,183],"at":[160,191,238,389,415],"1":[161,253,261,285],"2":[163],"levels":[165,395,408],"(DL):":[166],"DL1":[167],"=":[168,174],"50":[169],"\u00d7":[170,176],"106":[171,177],"or":[172],"DL2":[173,221,227,235],"100":[175],"CAR+":[178],"cells.":[180],"Durvalumab":[181],"IV":[186],"infusion":[187],"day":[189,390,397,410],"29":[190],"total":[193,242],"1500":[196,245],"mg/4":[197,246],"weeks":[198,247],"up":[200],"to":[201,278,307,318],"12":[202],"months.":[203],"Efficacy":[204],"assessed":[206],"per":[207],"Lugano":[209],"Classification.":[210],"Results:":[211],"At":[212],"cutoff,":[214],"18":[215],"were":[217,271,355],"enrolled":[218],"(DL1":[219,225,233],"n=9;":[220],"n=9).":[222],"15":[223],"n=8;":[226,234],"n=7)":[228],"liso-cel;":[230],"11":[231,268],"n=3)":[236],"completed":[237],"least":[239],"one":[240],"durvalumab":[241,319,334,340,428],"(2":[248],"are":[250],"awaiting":[251],"treatment;":[252],"pt":[254,262,343,400],"no":[255],"longer":[256],"met":[257],"eligibility":[259],"criteria;":[260],"died":[263,344],"sepsis).":[265],"Among":[266,374],"pts,":[269],"7":[270],"male;":[272],"age":[274],"ranged":[275],"53":[277],"78":[279],"years.":[280],"Ten":[281],"DLBCL;":[284],"patient":[286],"follicular":[288],"grade":[290,301,325],"3B.":[291],"Treatment-emergent":[292],"adverse":[293],"included":[295],"fever,":[296],"CRS,":[297],"NEs":[299],"(all":[300],"\u22642),":[302],"cytopenia,":[303],"fatigue":[305],"related":[306,317,327],"(n=7":[309],"pts);":[310],"hemolytic":[312],"anemia,":[313],"fatigue,":[314],"rash":[316],"(n=3":[320],"pts).":[321],"Two":[322],"\u22653":[326],"(neutropenic":[329],"fever":[330],"cytopenia)":[332],"after":[333,339,349,438],"treatment.":[335],"No":[336,352,434],"CRS":[337,435],"occurred":[338],"infusion.":[341],"One":[342,399],"acute":[346],"respiratory":[347],"failure":[348],"disease":[350],"progression.":[351],"dose-limiting":[353],"toxicities":[354],"observed.":[356],"best":[358],"overall":[359],"rate":[361],"91%":[363],"(10/11);":[364],"64%":[365],"(7/11)":[368],"achieved":[369,413],"complete":[371],"(CR).":[373],"first":[376],"6":[377],"who":[379],"durvalumab,":[381],"showed":[384],"increased":[385],"cells":[388,404,447],"85":[391,411],"compared":[392],"pre-durvalumab":[394],"on":[396,420],"29.":[398],"maintained":[401],"near":[405],"peak":[406],"expansion":[407],"until":[409],"CR":[414],"month":[416],"6.":[417],"Conclusions:":[418],"Based":[419],"results,":[422],"acceptable":[431],"safety":[432],"profile.":[433],"observed":[437],"initiation":[439],"Preliminary":[442],"suggest":[444],"persist":[448],"and/or":[449],"increase":[450],"treatment,":[453],"warranting":[454],"clinical":[456],"evaluation.":[457],"Updated":[458],"will":[460],"be":[461],"presented.":[462],"Keywords:":[463],"CD19;":[464],"(DLBCL);":[469],"PD-1L.":[470],"Disclosures:":[471],"Siddiqi,":[472],"T:":[473],"Consultant":[474,515,555,618],"Advisory":[475,516,556,619],"Role:":[476,517,557,620],"AstraZeneca,":[477],"Juno,":[478,490],"Pharmacyclics,":[479,505,659],"BeiGene;":[480],"Research":[481,538,550,565,641],"Funding:":[482,539,551,566,642],"Dr.":[483,567,643],"Siddiqi's":[484],"institution":[485,569,645],"research":[487,571,647],"funding":[488,572,648],"Celgene,":[491,542,558,575,623,650],"Kite,":[492,631],"BeiGene,":[493],"Oncternal":[494],"Therapeutics,":[495,526,630,639,657],"TG":[496,638,660],"therapeutics,":[497,545],"Acerta":[498],"Pharma,":[499],"Pharmacyclics;":[500],"Other":[501],"Remuneration:":[502],"Speaker":[503],"Janssen,":[506,531],"Seattle":[507,520,540,635],"Genetics.":[508],"Travel,":[509],"Accommodations,":[510],"Expenses:":[511],"Juno.":[512],"Abramson,":[513],"J:":[514,579,596],"Gilead":[518,625],"Sciences,":[519,626],"Genetics,":[521,541,636],"Celgene":[522,583],"Novartis,":[523,559,574,632],"Amgen,":[524],"Juno":[525,544,629,656],"Karyopharm,":[527],"Verastem,":[528],"Bayer,":[529,622],"Abbvie,":[530],"Merck,":[532,560,576],"Kite":[533],"Pharma":[534],"Genentech,":[535,543,561,624],"EMD":[536],"Serono;":[537],"AI":[546],"therapeutics.":[547],"Lee,":[548],"H:":[549],"Celgene.":[552,587,593,600,609,615],"Schuster,":[553],"S:":[554,589],"Nordic":[562],"Nanovector,":[563],"Gilead;":[564],"Schuster's":[568],"Genentech.":[577],"Hasskarl,":[578],"Employment":[580,590,597,603,612],"Leadership":[581,591,598,604,613],"Position:":[582,592,599,605,614],"International;":[584],"Stock":[585,607],"Ownership:":[586,608],"Montheard,":[588],"Dell":[594],"Aringa,":[595],"Thompson,":[601],"E:":[602],"Celgene;":[606],"Ananthakrishnan,":[610],"R:":[611],"Lunning,":[616],"M:":[617],"AbbVie,":[621],"Inc,":[627],"Janssen/Pharmacyclics,":[628],"Portola,":[633],"Sanofi-Genzyme,":[634],"Spectrum,":[637],"Verastem;":[640],"Lunning's":[644],"Curis,":[651],"Janssen":[652],"Scientific":[653],"Affairs,":[654],"LLC,":[655],"miRagen,":[658],"Therapeutics.":[661]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-06-27T00:00:00"}